Patents by Inventor Nigel W. Bunnett

Nigel W. Bunnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tripartite Modulators of Endosomal G Protein-Coupled Receptors
    Publication number: 20230119819
    Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
    Type: Application
    Filed: May 6, 2022
    Publication date: April 20, 2023
    Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
  • Tripartite modulators of endosomal G protein-coupled receptors
    Patent number: 11324832
    Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 10, 2022
    Assignee: Endosome Therapeutics, Inc.
    Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
  • Inhibitors of Protease Activated Receptor-2
    Publication number: 20200383985
    Abstract: The present invention relates generally to compounds capable of inhibiting Protease Activated Receptor-2 (PAR2), and uses thereof. More specifically, the present invention relates to inhibitors of PAR2, to their preparation, and to their use in the treatment of diseases and disorders mediated by PAR2 signaling.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 10, 2020
    Inventors: Luigi Aurelio, Nigel W. Bunnett, Bernhard Luke Flynn, Le Giang
  • TRIPARTITE MODULATORS OF ENDOSOMAL G PROTEIN-COUPLED RECEPTORS
    Publication number: 20190000981
    Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 3, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Nigel W. Bunnett, Christopher J.H. Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst
  • Ileus treatment method
    Patent number: 5958407
    Abstract: A method of treating or preventing post-operative ileus in a mammalian subject is disclosed. The method involves administering to the subject, a pharmaceutically effective amount of a compound that is effective in (i) preventing mast cell degranulation, (ii) inhibiting tryptase and chymase, and (iii) antagonizing PAR-2. The treatment is based on the discoveries that proteinase-activated receptor 2 is expressed in colonic muscle cells, and that activation of PAR-2 inhibits colonic motility. The PAR-2 receptor is activated, at least in part, by tryptase and chymase, produced by infiltration and degranulation of mast cells.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: September 28, 1999
    Assignee: The Regents of the Uinversity of California
    Inventors: Nigel W. Bunnett, Carlos U. Corvera
  • Ileus treatment method
    Patent number: 5888529
    Abstract: A method of treating or preventing post-operative ileus in a mammalian subject is disclosed. The method involves administering to the subject, a pharmaceutically effective amount of a compound that is effective in (i) preventing mast cell degranulation, (ii) inhibiting tryptase and chymase, and (iii) antagonizing PAR-2. The treatment is based on the discoveries that proteinase-activated receptor 2 is expressed in colonic muscle cells, and that activation of PAR-2 inhibits colonic motility. The PAR-2 receptor is activated, at least in part, by tryptase and chymase, produced by infiltration and degranulation of mast cells.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: March 30, 1999
    Assignee: The Regents of the University of California
    Inventors: Nigel W. Bunnett, Carlos U. Corvera